Jean-Pierre Malhaire

Author

Centre Hospitalier Régional Universitaire de Brest

Also Known As

J P Malhaire, Jean-Pierre Malhaire, Jean-pierre Malhaire, Malhaire, Jean-Pierre

Publications

759

Citations

H-Index

Concepts

All Affiliations

Centre Hospitalier Régional Universitaire de Brest Inserm Institut Gustave Roussy Centre Eugène Marquis Institut Claudius Regaud

About

Jean-Pierre Malhaire is an author at Centre Hospitalier Régional Universitaire de Brest specializing in medicine, radiation oncology, and pathology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	9	9	363
2	Pathology	6	6	321
3	Health Sciences	2	2	262
4	Obstetrics	1	1	11
5	Orthopaedics	1	1	16

Jean-Pierre Malhaire

Publications

720

Citations

H-Index

Page 1

	Year	Citations
Prediction of outcome using pretreatment 18F-FDG PET/CT and MRI radiomics in locally advanced cervical cancer treated with chemoradiotherapy François Lucia, Dimitris Visvikis, Marie-Charlotte Desseroit, European Journal of Nuclear Medicine and Molecular Imaging Advanced Cervical CancerPretreatment 18F-fdg Pet/ctCervical CancerMedical ImagingMri Radiomics	2017	247
Personalised chemotherapy based on tumour marker decline in poor prognosis germ-cell tumours (GETUG 13): a phase 3, multicentre, randomised trial Karim Fizazi, Lance C. Pagliaro, Agnès Laplanche, The Lancet Oncology UrologyMedicineCancer ManagementPathologyTumour Marker Decline	2014	197
Tamoxifen Adjuvant Treatment Duration in Early Breast Cancer: Initial Results of a Randomized Study Comparing Short-Term Treatment With Long-Term Treatment T. Delozier, M. Spielmann, Josette Macé-Lesec’h, Journal of Clinical Oncology	2000	51
A Risk-adapted Study of Cisplatin and Etoposide, with or Without Ifosfamide, in Patients with Metastatic Seminoma: Results of the GETUG S99 Multicenter Prospective Study Karim Fizazi, R. Delva, Armelle Caty, European Urology UrologyMetastatic SeminomaGenitourinary CancerMedicinePathology	2013	51
A phase III trial of personalized chemotherapy based on serum tumor marker decline in poor-prognosis germ-cell tumors: Results of GETUG 13. Karim Fizazi, Lance C. Pagliaro, Aude Fléchon, Journal of Clinical Oncology UrologyMalignant DiseaseMedicineCancer ManagementPhase Iii Trial	2013	31
[Fotemustine (Muphoran) in 22 patients with relapses of high-grade cerebral gliomas]. Jean-Pierre Malhaire, B. Lucas, H. Simon, PubMed	1999	18
Dose to the penile bulb and individual patient anatomy are predictive of erectile dysfunction in men treated with <sup>125</sup>I low dose rate brachytherapy for localized prostate cancer Matthieu Chasseray, Gurvan Dissaux, Vincent Bourbonne, Acta Oncologica	2019	16
Post-fracture osteolysis of the pubic bone simulating a malignancy Estelle Botton, Alain Saraux, Jean-Pierre Malhaire, Joint Bone Spine Bone DiseaseOsteoarthritisFracture HealingSurgeryMedicine	2004	16
One Case of Stewart-Treves Syndrome Successfully Treated at Two Years by Chemotherapy and Radiation Therapy in a 73-year-old Woman Jean-Pierre Malhaire, Jean-Paul Labat, H. Simon, Acta Oncologica MedicineRadiation Oncology73-Year-old WomanRadiation Therapy	1997	15
Mature results of the GETUG 13 phase III trial in poor-prognosis germ-cell tumors (GCT). Karim Fizazi, Aude Fléchon, Gwénaël Le Teuff, Journal of Clinical Oncology Surgical OncologyCancer ManagementPathologyPoor-prognosis GctMetronomic Chemotherapy	2016	15

Page 1